Inari Medical, Inc. (NASDAQ:NARI) CEO William Hoffman sold 150,000 shares of Inari Medical stock in a transaction dated Monday, April 5th. The stock was sold at an average price of $106.40, for a total transaction of $15,960,000.00. Following the transaction, the chief executive officer now directly owns 1,049,478 shares in the company, valued at $111,664,459.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
William Hoffman also recently made the following trade(s):
- On Friday, March 5th, William Hoffman sold 30,000 shares of Inari Medical stock. The shares were sold at an average price of $92.47, for a total transaction of $2,774,100.00.
- On Wednesday, January 20th, William Hoffman sold 20,000 shares of Inari Medical stock. The shares were sold at an average price of $100.68, for a total transaction of $2,013,600.00.
- On Wednesday, January 13th, William Hoffman sold 30,000 shares of Inari Medical stock. The stock was sold at an average price of $90.60, for a total value of $2,718,000.00.
Shares of NARI stock opened at $111.01 on Thursday. Inari Medical, Inc. has a fifty-two week low of $39.55 and a fifty-two week high of $127.42. The company has a 50 day moving average price of $108.01 and a 200 day moving average price of $86.31.
Inari Medical (NASDAQ:NARI) last posted its quarterly earnings data on Monday, March 8th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.12. The company had revenue of $48.60 million for the quarter, compared to analysts’ expectations of $41.49 million. The firm’s quarterly revenue was up 144.2% compared to the same quarter last year. As a group, research analysts predict that Inari Medical, Inc. will post 0.15 EPS for the current year.
NARI has been the topic of several recent analyst reports. Wells Fargo & Company upped their price target on Inari Medical from $112.00 to $125.00 and gave the company an “overweight” rating in a research note on Tuesday, March 16th. Canaccord Genuity reiterated a “buy” rating and set a $129.00 price target (up from $94.00) on shares of Inari Medical in a research report on Tuesday, March 16th. Morgan Stanley increased their price objective on shares of Inari Medical from $85.00 to $126.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 16th. BTIG Research boosted their target price on Inari Medical from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, March 10th. Finally, SVB Leerink upped their price target on Inari Medical from $116.00 to $126.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 16th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Inari Medical has an average rating of “Buy” and an average price target of $110.86.
A number of hedge funds have recently bought and sold shares of NARI. Charles Schwab Investment Management Inc. boosted its stake in shares of Inari Medical by 0.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 57,961 shares of the company’s stock valued at $5,060,000 after buying an additional 223 shares during the period. Horan Securities Inc. acquired a new stake in Inari Medical in the fourth quarter valued at approximately $27,000. First Horizon Advisors Inc. purchased a new position in Inari Medical in the fourth quarter worth approximately $28,000. MUFG Americas Holdings Corp acquired a new position in Inari Medical during the 4th quarter worth approximately $70,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Inari Medical by 20.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 4,814 shares of the company’s stock valued at $420,000 after purchasing an additional 830 shares during the last quarter. 17.77% of the stock is currently owned by institutional investors.
Inari Medical Company Profile
Inari Medical, Inc, a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It offers ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism.
Further Reading: Catch-Up Contributions
Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.